Proto-Oncogene Proteins
Research News and Information

Monday, November 23, 2009

EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy.

13 Nov 2009 Sarcomatoid carcinomas (SC) of the lung are uncommon malignant tumors composed of carcinomatous and sarcomatous cell components and characterized by a more aggressive outcome than other histological subtypes of nonsmall cell lung cancer (NSCLC). ... Read more...

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.

13 Nov 2009 Mutations in KRAS or BRAF frequently manifest in constitutive activation of the MEK1/2-ERK1/2 signalling pathway. The MEK1/2-selective inhibitor, AZD6244 (ARRY-142886), blocks ERK1/2 activation and is currently undergoing clinical evaluation. Tumour ... Read more...

The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.

13 Nov 2009 The spectrum of tumors showing microsatellite instability (MSI) has recently been enlarged to sporadic neoplasms whose incidence is favored in the context of chronic immunosuppression. We investigated the biological, therapeutic and clinical ... Read more...

Latest indexed articles for 'Proto-Oncogene Proteins'

These are the very latest articles for this heading:

• Novel multiple, monoallelic KRAS mutations at codon 12 and 13. 29 Nov 2009
• EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. 13 Nov 2009
• Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. 13 Nov 2009
• The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. 13 Nov 2009
• Necdin: a multi functional protein with potential tumor suppressor role? 30 Oct 2009
• Clinical implication of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in patients with acute paraquat intoxication. 30 Oct 2009
• Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report. 30 Oct 2009
• In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. 30 Oct 2009
• TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors. 30 Oct 2009
• IRAK1-independent pathways required for the interleukin-1-stimulated activation of the Tpl2 catalytic subunit and its dissociation from ABIN2. 21 Oct 2009
• PU.1 regulates TCR expression by modulating GATA-3 activity. 13 Oct 2009
• RAS and CSF3R mutations in severe congenital neutropenia. 13 Oct 2009
• Impaired TNFalpha-induced A20 expression in E1A/Ras-transformed cells. 11 Oct 2009
• A recurrent network involving the transcription factors PU.1 and Gfi1 orchestrates innate and adaptive immune cell fates. 6 Oct 2009
• Neutrophil gelatinase-associated lipocalin in the intensive care unit: time to look beyond a single, threshold-based measurement? 29 Sep 2009
• LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. 29 Sep 2009
• Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. 29 Sep 2009
• CCM2 and CCM3 proteins contribute to vasculogenesis and angiogenesis in human placenta. 29 Sep 2009
• Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. 29 Sep 2009
• The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. 29 Sep 2009

See a longer list of these articles.

Technical information about 'Proto-Oncogene Proteins'

Definition: Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.

Registry Number: 0

Descriptor UI: D011518

Alternative terms: Proto-Oncogene Proteins; Proto Oncogene Proteins; Proto-Oncogene Products, Cellular; Cellular Proto-Oncogene Products; Proto Oncogene Products, Cellular; Proto Oncogene Proteins, Cellular; c-onc Proteins; c onc Proteins; Cellular Proto-Oncogene Proteins; Cellular Proto Oncogene Proteins; Proto-Oncogene Proteins, Cellular;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.776.624.664.700;

Online Note: use PROTO-ONCOGENE PROTEINS to search PROTO-ONCOGENE PROTEINS, CELLULAR 1986-90

History Note: 91; was PROTO-ONCOGENE PROTEINS, CELLULAR 1986-90

Technical Notes: GEN or unspecified; prefer specifics; /drug eff /ultrastruct permitted; DF: note short X ref